Cefalexin monohydrate 50 mg/mL (=Cephalexin 50 mg/mL) - search results

aspen pharmacare australia pty ltd - cefalexin monohydrate, quantity: 500 mg - capsule, hard - excipient ingredients: dimeticone 350; magnesium stearate; patent blue v; quinoline yellow; titanium dioxide; gelatin; microcrystalline cellulose; carmellose sodium; purified water; shellac; industrial methylated spirit; iron oxide black; 2-ethoxyethanol; dimeticone 1000; lecithin - indications as at 24 february 2004: keflex is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: respiratory tract infections caused by s. pneumoniae and group a beta-haemolytic streptococci (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. keflex is generally effective in the eradication of streptococci from nasopharynx; however, substantial data establishing the efficacy of keflex in the subsequent prevention of rheumatic fever are not available at present.) bacterial sinusitis caused by streptococci, s. pneumoniae and s. aureus (methicillin-sensitive only) otitis media due to s. pneumoniae, staphylococci; skin and soft tissue infections caused by staphlococci anr/or streptococci; genitourinary tract infections, including acute prostatic caused by e. coli, p. mirabilis, and klebsiella sp. the effectiveness of keflex in the treatment of bacterial infections of the brain and spinal column has not been established and keflex is not indicated in these conditions. note: appropriate culture and susceptibility test should be initiated prior to and during therapy to determine susceptibility of the causative organism to keflex. renal function studies should be performed when indicated.

Australia - English - Department of Health (Therapeutic Goods Administration)

cephalexin

lupin australia pty limited - cefalexin, quantity: 500 mg - capsule - excipient ingredients: microcrystalline cellulose; magnesium stearate - respiratory tract infections caused by s. pneumoniae and group a beta-haemolytic streptococci (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cephalexin max capsule is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin capsule in the subsequent prevention of rheumatic fever are not available at present). bacterial sinusitis caused by streptococci, s. pneumoniae and s. aureus (methicillin sensitive only). otitis media. due to s. pneumoniae, staphylococci. skin and soft tissue infections. caused by staphylococci and/or streptococci. genitourinary tract infections, including acute prostatitis caused by e. coli, p. mirabilis and klebsiella sp. the effectiveness of cephalexin max capsule in the treatment of bacterial infections of the brain and spinal column has not been established and cephalexin max capsule is not indicated in these conditions. note: appropriate culture and susceptibility tests should be initiated prior to and during therapy to determine susceptibility of the causative organism to cephalexin max capsule. renal function studies should be performed when indicated.

Australia - English - Department of Health (Therapeutic Goods Administration)

genrx cephalexin cefalexin (as monohydrate) 250mg/5ml powder for suspension bottle

arrotex pharmaceuticals pty ltd - cefalexin monohydrate, quantity: 50 mg/ml (equivalent: cefalexin monohydrate, qty 52.576 mg/ml) - suspension, powder for - excipient ingredients: citric acid; sucrose; iron oxide yellow; saccharin sodium; guar galactomannan; simethicone; sodium benzoate; flavour - treatment of the following infections when caused by susceptible strains of the designated microorganisms. respiratory tract infections. caused by s. pneumoniae and group a beta-haemolytic streptococci (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cephalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present). bacterial sinusitis. caused by streptococci, s. pneumoniae and s. aureus (methicillin sensitive only). otitis media. due to s. pneumoniae, staphylococci. skin and skin structure infections. caused by staphylococci and/or streptococci. genitourinary tract infections, including acute prostatitis. caused by e. coli, p. mirabilis, and klebsiella sp. the effectiveness of cephalexin in the treatment of bacterial infections of the brain and spinal column has not been established and cephalexin is not indicated in these conditions. note: appropriate culture and susceptibility tests should be initiated prior to and during therapy to determine susceptibility of the causative organism to cephalexin. renal function studies should be performed when indicated.

Australia - English - Department of Health (Therapeutic Goods Administration)

genrx cephalexin cefalexin (as monohydrate) 125mg/5ml powder for suspension bottle

arrotex pharmaceuticals pty ltd - cefalexin monohydrate, quantity: 25 mg/ml (equivalent: cefalexin monohydrate, qty 26.288 mg/ml) - suspension, powder for - excipient ingredients: sucrose; guar galactomannan; saccharin sodium; sodium benzoate; iron oxide yellow; simethicone; citric acid; flavour - treatment of the following infections when caused by susceptible strains of the designated microorganisms. respiratory tract infections. caused by s. pneumoniae and group a beta-haemolytic streptococci (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cephalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present). bacterial sinusitis. caused by streptococci, s. pneumoniae and s. aureus (methicillin sensitive only). otitis media. due to s. pneumoniae, staphylococci. skin and skin structure infections. caused by staphylococci and/or streptococci. genitourinary tract infections, including acute prostatitis. caused by e. coli, p. mirabilis, and klebsiella sp. the effectiveness of cephalexin in the treatment of bacterial infections of the brain and spinal column has not been established and cephalexin is not indicated in these conditions. note: appropriate culture and susceptibility tests should be initiated prior to and during therapy to determine susceptibility of the causative organism to cephalexin. renal function studies should be performed when indicated.